Open AccessOlaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation
Author(s) -
Fengjiao Zhao,
Yong Zhou,
Poshita Kumari Seesaha,
Yihong Zhang,
Siqin Liu,
Xiaoyan Gan,
Jun Hu,
Yanhong Gu,
Xiaofeng Chen
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000022312
Subject(s) - medicine , olaparib , nivolumab , germline mutation , oncology , germline , parp inhibitor , ovarian cancer , cancer , immunotherapy , liver cancer , cancer research , mutation , polymerase , poly adp ribose polymerase , biochemistry , chemistry , gene
Rationale: Immunotherapy and targeted therapy have attracted widespread attention in current clinical research, which could be considered as a good therapeutic option for treatment of refractory liver cancer. Patient concerns: The patient was a 37-year-old man with hepatitis B virus (HBV) infection. He was presented with hepatalgia and discomfort. Diagnosis: The computed tomography showed multiple intrahepatic masses, indicating primary liver cancer with multiple intrahepatic metastases. Interventions: After failed transarterial chemoembolization therapy, he was initially treated with immunotherapy pembrolizumab plus angiogenesis inhibitor lenvatinib, and after 3 months of treatment, the condition improved. However, the disease subsequently progressed. The next-generation sequencing identified a BRCA2 germline mutation in this patient. A poly (ADP-ribose) polymerase inhibitor, olaparib, plus nivolumab therapy was started and achieved stable disease. Outcomes: The patient achieved stable disease and improvement in hepatalgia for 3 months after the combination treatment of Olaparib and nivolumab. Conclusion: We identified a BRCA2 germline mutation in a patient with liver cancer. Our findings could offer an alternative management for patients with liver cancer harboring germline BRCA2 mutation.